Skip to Content
Merck
CN
  • Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).

Generation of fourteen isogenic cell lines for Parkinson's disease-associated leucine-rich repeat kinase (LRRK2).

Stem cell research (2021-06-06)
Aleksandra Beylina, Rebekah G Langston, Dorien Rosen, Xylena Reed, Mark R Cookson
ABSTRACT

Mutations in leucine-rich repeat kinase 2 (LRRK2) are associated with inherited forms of Parkinson's disease (PD), causing disease by a gain of kinase function. Here, we describe a series of isogenic iPSC lines with any of five pathogenic mutations (N1437H, R1441C, Y1699C, G2019S and I2020T); two hypothesis testing mutations (GTP binding null, T1348N, and kinase dead, K1906M) and two LRRK2 knockouts. This resource could be used to assess effects of mutations on the function of endogenous LRRK2 and/or to study LRRK2 interactors and substrates in iPSC-derived cellular models.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-SOX-2 Antibody, clone 10H9.1, clone 10H9.1, from mouse
Sigma-Aldrich
Anti-NANOG Antibody, clone 7F7.1, clone 7F7.1, from mouse
Sigma-Aldrich
Anti-Nestin, Human Antibody, serum, from rabbit